Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41 | $41 | $44 | $39 |
| % Growth | -0.8% | -5.8% | 12.7% | – |
| Cost of Goods Sold | $21 | $22 | $23 | $20 |
| Gross Profit | $20 | $20 | $21 | $19 |
| % Margin | 48% | 47.8% | 47.3% | 48.1% |
| R&D Expenses | $4 | $4 | $4 | $4 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $6 | $7 | $10 | $10 |
| Sales & Mktg Exp. | $5 | $6 | $9 | $9 |
| Other Operating Expenses | $5 | $5 | $3 | $2 |
| Operating Expenses | $15 | $16 | $17 | $16 |
| Operating Income | $4 | $3 | $8 | $6 |
| % Margin | 10.3% | 8% | 18.9% | 16.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$2 | -$2 |
| Pre-Tax Income | $4 | $3 | $5 | $6 |
| Tax Expense | $1 | $0 | $1 | $1 |
| Net Income | $3 | $2 | $4 | $5 |
| % Margin | 6.7% | 5.8% | 8.5% | 12.1% |
| EPS | 1.04 | 0.89 | 1.43 | 1.85 |
| % Growth | 16.9% | -37.8% | -22.7% | – |
| EPS Diluted | 1.04 | 0.89 | 1.43 | 1.85 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $3 | $2 | $2 |
| EBITDA | $9 | $6 | $8 | $9 |
| % Margin | 20.9% | 13.4% | 17.9% | 22.6% |